Initiation of phase III clinical trial of BAN2401 in early Alzheimer's disease
Eisai Co. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen. March 22, 2019